Global Heparin API Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Heparin API Market Insights, Forecast to 2034
Heparin, a highly sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machine.
Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium.
This report is revolving around Heparin Active Pharmaceutical Ingredients (API).
Global Heparin API market is expected to reach to US$ 3017.2 million in 2024, with a positive growth of %, compared with US$ 2635.1 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Heparin API industry is evaluated to reach US$ 6116.8 million in 2029. The CAGR will be 12.5% during 2024 to 2029.
Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium.
The market driver mainly increasing prevalence of conditions such as renal impairment, coronary artery disease, and venous thromboembolism, High demand for anticoagulants, etc.
In recent years, with the impact of African swine fever and the outbreak of COVID-19. Heparin as a resource-based industry expected to be in a state of tight supply for a period in the future, and the tight supply state may drive the sales price of heparin products to rise, the future driving force of the industry is more obvious, and the long-term profitability is more certain. The price of heparin has ushered in a major upward cycle since 2016. The main reason is that China is the main supplier of live pigs in the world. The raging African swine fever has greatly reduced the supply of live pigs, driving the price of heparin to rise sharply.
Asia-Pacific is the largest consumption place, with a revenue market share nearly 35% in 2022. Mainly China is the worlds’ largest pig production, which supplied by sufficient raw materials. Following Asia-Pacific, Europe is the second largest consumption place with the revenue market share nearly 34%.
The global key manufacturers of Heparin include Shenzhen Hepalink Pharmaceutical, Yantai Dongcheng Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Pfizer, Hebei Changshan Biochemical Pharmaceutical, Bioibérica, Qingdao Jiulong Biopharmaceutical, Changzhou Qianhong Biopharma, and etc. In 2022, the global top five players hold a share approximately 57% in terms of revenue.
Report Covers
This report presents an overview of global Heparin API market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Heparin API market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Shenzhen Hepalink Pharmaceutical
Yantai Dongcheng Pharmaceutical
Nanjing King-friend Biochemical Pharmaceutical
Pfizer
Hebei Changshan Biochemical Pharmaceutical
Bioibérica
Qingdao Jiulong Biopharmaceutical
Changzhou Qianhong Biopharma
Dongying Tiandong Pharmaceutical
Opocrin
Hubei Enoray Biopharmaceutical
Yino Pharma
Cisen Pharmaceutical
Nanjing Xinbai Pharmaceutical
Sichuan Deebio Pharmaceutical
Segment by Type
Heparin Sodium
Heparin Calcium
UFH
LMWH
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Heparin API plant distribution, commercial date of Heparin API, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Heparin API introduction, etc. Heparin API Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Heparin API
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium.
This report is revolving around Heparin Active Pharmaceutical Ingredients (API).
Global Heparin API market is expected to reach to US$ 3017.2 million in 2024, with a positive growth of %, compared with US$ 2635.1 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Heparin API industry is evaluated to reach US$ 6116.8 million in 2029. The CAGR will be 12.5% during 2024 to 2029.
Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium.
The market driver mainly increasing prevalence of conditions such as renal impairment, coronary artery disease, and venous thromboembolism, High demand for anticoagulants, etc.
In recent years, with the impact of African swine fever and the outbreak of COVID-19. Heparin as a resource-based industry expected to be in a state of tight supply for a period in the future, and the tight supply state may drive the sales price of heparin products to rise, the future driving force of the industry is more obvious, and the long-term profitability is more certain. The price of heparin has ushered in a major upward cycle since 2016. The main reason is that China is the main supplier of live pigs in the world. The raging African swine fever has greatly reduced the supply of live pigs, driving the price of heparin to rise sharply.
Asia-Pacific is the largest consumption place, with a revenue market share nearly 35% in 2022. Mainly China is the worlds’ largest pig production, which supplied by sufficient raw materials. Following Asia-Pacific, Europe is the second largest consumption place with the revenue market share nearly 34%.
The global key manufacturers of Heparin include Shenzhen Hepalink Pharmaceutical, Yantai Dongcheng Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Pfizer, Hebei Changshan Biochemical Pharmaceutical, Bioibérica, Qingdao Jiulong Biopharmaceutical, Changzhou Qianhong Biopharma, and etc. In 2022, the global top five players hold a share approximately 57% in terms of revenue.
Report Covers
This report presents an overview of global Heparin API market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Heparin API market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Shenzhen Hepalink Pharmaceutical
Yantai Dongcheng Pharmaceutical
Nanjing King-friend Biochemical Pharmaceutical
Pfizer
Hebei Changshan Biochemical Pharmaceutical
Bioibérica
Qingdao Jiulong Biopharmaceutical
Changzhou Qianhong Biopharma
Dongying Tiandong Pharmaceutical
Opocrin
Hubei Enoray Biopharmaceutical
Yino Pharma
Cisen Pharmaceutical
Nanjing Xinbai Pharmaceutical
Sichuan Deebio Pharmaceutical
Segment by Type
Heparin Sodium
Heparin Calcium
Segment by Application
UFH
LMWH
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Heparin API plant distribution, commercial date of Heparin API, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Heparin API introduction, etc. Heparin API Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Heparin API
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices